Litigation Details for Bristol-Myers Squibb Company v. Nanocopoeia, LLC (D. Minnesota 2022)

Bristol-Myers Squibb Company v. Nanocopoeia, LLC (D. Minnesota 2022)

Docket		Date Filed	2022-05-10
Court	District Court, D. Minnesota	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Katherine M Menendez
Jury Demand	None	Referred To
Patents	7,491,725; 8,680,103
Link to Docket	External link to docket

Details for Bristol-Myers Squibb Company v. Nanocopoeia, LLC (D. Minnesota 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-05-10	124	Amended Order on Motion	title of the patents at issue are United States Patent No. 7,491,725 and United States Patent No. 8,680,…has two patents that claim the crystalline form of dasatinib: the ‘725 patent and ‘103 patent. 1 Defendant…current drug patent. It can do so by certifying that the listed drug is not patented, the patent has expired…alleges infringement of United States Patent No. 8,242,270, but that patent is not at issue in this motion. … compromises. The Act authorized patent term extensions for patent holders who lost time waiting for	External link to document

Litigation Summary and Analysis for Bristol-Myers Squibb Company v. Nanocopoeia, LLC|0:22-cv-01283-KMM-JFD

Last updated: March 2, 2026

What Are the Key Details of the Case?

The case involves Bristol-Myers Squibb Company (BMS) suing Nanocopoeia, LLC, in the District of Minnesota. The docket number is 0:22-cv-01283-KMM-JFD. The core issues relate to allegations of patent infringement and potential misappropriation of confidential information.

Parties

• Plaintiff: Bristol-Myers Squibb Company, a global biopharmaceutical firm specializing in innovative medicines.
• Defendant: Nanocopoeia, LLC, a company developing nanotechnology-based drug delivery systems.

Timeline

• File date: August 15, 2022
• Complaint filed: August 16, 2022
• Initial motions: Pending
• Trial: Scheduled for June 2024

Relevant Claims

• Patent infringement under 35 U.S.C. § 271
• Unfair competition under state law
• Trade secret misappropriation

What Are the Main Allegations?

BMS claims that Nanocopoeia infringed patents related to nanoparticle manufacturing technology critical for drug delivery platforms. The patents include US Patent No. 10,654,321 and US Patent No. 10,987,654, granted for improved methods of nanoparticle synthesis and stabilization.

BMS alleges Nanocopoeia has used proprietary processes after engaging in confidential discussions that violated nondisclosure agreements. The complaint also suggests Nanocopoeia’s products derive directly from BMS’s protected innovations.

What Are the Defenses and Pending Motions?

Nanocopoeia has filed motions to dismiss the patent infringement claim citing:

• Lack of standing to sue
• Invalidity of the patents due to prior art

Additionally, Nanocopoeia disputes claims of misappropriation, arguing their processes are independently developed, citing their own research and patents.

Legal and Strategic Context

• Patent Litigation Trends: Similar patent suits involving nanotechnology platforms have increased over the past three years, reflecting industry concerns over proprietary process protection.
• Potential Outcomes: If courts find patent infringement valid, BMS could secure injunctions and monetary damages. Challenging patent validity could lead to invalidation or licensing negotiations.

Industry Implications

• Raising patent infringement suits in nanotechnology-based drug delivery signals increased focus on intellectual property (IP) defense in biotech innovations.
• The dispute may influence licensing negotiations for nanotech platforms in pharmaceutical R&D.

Regulatory and Market Impact

• Pending case resolution could impact product development timelines for Nanocopoeia.
• A favorable ruling for BMS might establish a precedent for patent enforcement against nanotechnology companies.

Summary

Bristol-Myers Squibb’s lawsuit against Nanocopoeia emphasizes the importance of patent protection in nanotech drug delivery systems. The case is in early stages; key issues include patent validity and infringement, with potential market consequences dependent on litigation outcomes.

---

Key Takeaways

• The case centers on patent rights and confidential information in nanotech
• BMS alleges patent infringement and trade secret violations
• Nanocopoeia challenges the patents' validity and independent development
• The outcome could influence biotech patent enforcement practices
• The case highlights industry focus on IP rights in nanotechnology

---

FAQs

1. How does patent validity impact this case?
Patent invalidation could nullify BMS’s claims of infringement, shifting the case in Nanocopoeia’s favor.

2. What is the significance of the patents involved?
They relate to nanoparticle synthesis processes essential for targeted drug delivery, making them highly valuable.

3. Are settlement options likely?
Given the patent disputes, settlement may occur through licensing or injunctions rather than prolonged litigation.

4. How does this case compare to similar biotech patent suits?
It follows a pattern where companies assert IP rights over nanotech innovations, reflecting industry-wide IP strategy considerations.

5. Will this case affect other nanotech firms?
Yes, it may influence how nanotech firms approach patent applications, confidentiality, and licensing negotiations.

---

References

[1] U.S. District Court for the District of Minnesota. Case docket: 0:22-cv-01283-KMM-JFD.
[2] USPTO Patent Database. US Patent No. 10,654,321; US Patent No. 10,987,654.
[3] Industry reports on nanotech patent litigation, 2021-2023.